BioCentury
ARTICLE | Clinical News

Spark, Alnylam update hemophilia data

December 6, 2016 12:54 AM UTC

Spark Therapeutics Inc. (NASDAQ:ONCE) and Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) released updated results from ongoing hemophilia trials at the American Society of Hematology (ASH) meeting in San Diego.

Spark gained $0.58 to $50.58 on Monday, as investors appeared relatively unperturbed by immune responses in patients receiving SPK-9001. On Saturday, the company and partner Pfizer Inc. (NYSE:PFE) reported a second immune response among nine patients receiving the gene therapy in an ongoing Phase I/II study to treat hemophilia B, about a month after reporting the first. Both are related to the therapy's adeno-associated virus (AAV) capsid (see BioCentury Extra, Nov. 3)...